Home>BUSINESS

Daiichi Sankyo to Shed Non-Cancer R&D Costs, Allocate More Resources to Oncology: CEO(Dec.14.2017)
Daiichi Sankyo CEO Joji Nakayama |
Daiichi Sankyo is re-allocating its R&D investments as the company works to expedite the development of its key oncology candidates including HER2-targeting antibody drug conjugate (ADC) DS-8201, Chairman and CEO Joji Nakayama revealed ...
(LOG IN FOR FULL STORY)
- Takeda in Talks with Shire after 3 Buyout Proposals Rejected Apr.20
- Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers Apr.20
- Toho Grabs 8% Stake in NKT Cell Immunotherapy Startup Apr.19
- Astellas Sells Agensys Research Facilities to Kite Apr.19
- US Appeals Court Favors Sumitomo Dainippon in Latuda Substance Patent Suit Apr.19